Search

Your search keyword '"Fardon, Thomas C."' showing total 31 results
Start Over Author "Fardon, Thomas C."
31 results on '"Fardon, Thomas C."'

5. Characterization of bronchiectasis in the elderly

Author

Bellelli, Giuseppe, Chalmers, James D., Sotgiu, Giovanni, Dore, Simone, McDonnell, Melissa J., Goeminne, Pieter C., Dimakou, Katerina, Skrbic, Dusan, Lombi, Andrea, Pane, Federico, Obradovic, Dusanka, Fardon, Thomas C., Rutherford, Robert M., Pesci, Alberto, and Aliberti, Stefano

Published
2016
Full Text
View/download PDF

9. Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis

Author

Aliberti, Stefano, primary, Sotgiu, Giovanni, additional, Gramegna, Andrea, additional, McDonnell, Melissa J., additional, Polverino, Eva, additional, Torres, Antoni, additional, Goeminne, Pieter C., additional, Dimakou, Katerina, additional, Shteinberg, Michal, additional, Sibila, Oriol, additional, Conio, Valentina, additional, Fardon, Thomas C., additional, Rutherford, Robert, additional, Dore, Simone, additional, Saderi, Laura, additional, Faverio, Paola, additional, Amati, Francesco, additional, Corsico, Angelo G., additional, Blasi, Francesco, additional, and Chalmers, James D., additional

Published
2021
Full Text
View/download PDF

14. Endotyping bronchiectasis through multi-omic profiling

Author

Keir, Holly Rachael, primary, Shoemark, Amelia, additional, Crichton, Megan, additional, Dicker, Alison, additional, Pollock, Jennifer, additional, Giam, Ashley, additional, Cassidy, Andrew, additional, Fong, Christopher, additional, Finch, Simon, additional, Furrie, Elizabeth, additional, Suarez-Cuartin, Guillermo, additional, Fardon, Thomas C, additional, Einarsson, Gisli G, additional, Elborn, J Stuart, additional, Aliberti, Stefano, additional, Sibila, Oriol, additional, Huang, Jeffrey T-J, additional, and Chalmers, James D, additional

Published
2020
Full Text
View/download PDF

16. Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis

Author

Finch, Simon, primary, Shoemark, Amelia, additional, Dicker, Alison J., additional, Keir, Holly R., additional, Smith, Alexandria, additional, Ong, Samantha, additional, Tan, Brandon, additional, Choi, Jean-Yu, additional, Fardon, Thomas C., additional, Cassidy, Diane, additional, Huang, Jeffrey T. J., additional, and Chalmers, James D., additional

Published
2019
Full Text
View/download PDF

20. The Sputum Microbiome Is Associated with Lung Inflammation, Exacerbations and Mortality in Patients with Bronchiectasis

Author

Dicker, Alison J., primary, Keir, Holly R., additional, Lonergan, Mike, additional, Smith, Alexandria H., additional, Fong, Christopher J., additional, Tan, Brandon, additional, Pollock, Jennifer, additional, Finch, Simon, additional, Fardon, Thomas C., additional, Cassidy, Andrew J., additional, Huang, Jeffrey T. J., additional, and Chalmers, James D., additional

Published
2019
Full Text
View/download PDF

22. Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis.

Author

Yong-hua Gao, Leyah, Hani Abo, Finch, Simon, Lonergan, Mike, Aliberti, Stefano, De Soyza, Anthony, Fardon, Thomas C., Tino, Gregory, Chalmers, James D., Gao, Yong-Hua, and Abo Leyah, Hani

Subjects
SYMPTOMS, DISEASE exacerbation, BRONCHIECTASIS, COHORT analysis, MACROLIDE antibiotics, DISEASE progression, RESEARCH, RESPIRATORY therapy equipment, RESEARCH methodology, MANNITOL, EVALUATION research, MEDICAL cooperation, COMPARATIVE studies, HOSPITAL care, QUALITY of life, COUGH, FORCED expiratory volume, PSEUDOMONAS diseases, INHALATION administration, LONGITUDINAL method, PROPORTIONAL hazards models
Abstract

Rationale: Bronchiectasis guidelines regard treatment to prevent exacerbation and treatment of daily symptoms as separate objectives.Objectives: We hypothesized that patients with greater symptoms would be at higher risk of exacerbations and therefore that a treatment aimed at reducing daily symptoms would also reduce exacerbations in highly symptomatic patients.Methods: Our study comprised an observational cohort of 333 patients from the East of Scotland (2012-2016). Either symptoms were modeled as a continuous variable or patients were classified as having high, moderate, or low symptom burden (>70, 40-70, and <40 using the St. George's Respiratory Questionnaire symptom score). The hypothesis that exacerbation reductions would only be evident in highly symptomatic patients was tested in a post hoc analysis of a randomized trial of inhaled dry powder mannitol (N = 461 patients).Measurements and Main Results: In the observational cohort, daily symptoms were a significant predictor of future exacerbations (rate ratio [RR], 1.10; 95% confidence interval [CI], 1.03-1.17; P = 0.005). Patients with higher symptom scores had higher exacerbation rates (RR, 1.74; 95% CI, 1.12-2.72; P = 0.01) over 12-month follow-up than those with lower symptoms. Inhaled mannitol treatment improved the time to first exacerbation (hazard ratio, 0.56; 95% CI, 0.40-0.77; P < 0.001), and the proportion of patients remaining exacerbation free for 12 months of treatment was higher in the mannitol group (32.7% vs. 14.6%; RR, 2.84; 95% CI, 1.40-5.76; P = 0.003), but only in highly symptomatic patients. In contrast, no benefit was evident in patients with lower symptom burden.Conclusions: Highly symptomatic patients have increased risk of exacerbations, and exacerbation benefit with inhaled mannitol was only evident in patients with high symptom burden. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

23. Characterization of the “Frequent Exacerbator Phenotype” in Bronchiectasis

Author

Chalmers, James D., primary, Aliberti, Stefano, additional, Filonenko, Anna, additional, Shteinberg, Michal, additional, Goeminne, Pieter C., additional, Hill, Adam T., additional, Fardon, Thomas C., additional, Obradovic, Dusanka, additional, Gerlinger, Christoph, additional, Sotgiu, Giovanni, additional, Operschall, Elisabeth, additional, Rutherford, Robert M., additional, Dimakou, Katerina, additional, Polverino, Eva, additional, De Soyza, Anthony, additional, and McDonnell, Melissa J., additional

Published
2018
Full Text
View/download PDF

24. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis

Author

Araújo, David, primary, Shteinberg, Michal, additional, Aliberti, Stefano, additional, Goeminne, Pieter C., additional, Hill, Adam T., additional, Fardon, Thomas C., additional, Obradovic, Dusanka, additional, Stone, Glenda, additional, Trautmann, Marion, additional, Davis, Angela, additional, Dimakou, Katerina, additional, Polverino, Eva, additional, De Soyza, Anthony, additional, McDonnell, Melissa J., additional, and Chalmers, James D., additional

Published
2018
Full Text
View/download PDF

25. Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With Bronchiectasis

Author

De Soyza, Anthony, primary, McDonnell, Melissa J., additional, Goeminne, Pieter C., additional, Aliberti, Stefano, additional, Lonni, Sara, additional, Davison, John, additional, Dupont, Lieven J., additional, Fardon, Thomas C., additional, Rutherford, Robert M., additional, Hill, Adam T., additional, and Chalmers, James D., additional

Published
2017
Full Text
View/download PDF

26. Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis

Author

Chalmers, James D., primary, Moffitt, Kelly L., additional, Suarez-Cuartin, Guillermo, additional, Sibila, Oriol, additional, Finch, Simon, additional, Furrie, Elizabeth, additional, Dicker, Alison, additional, Wrobel, Karolina, additional, Elborn, J. Stuart, additional, Walker, Brian, additional, Martin, S. Lorraine, additional, Marshall, Sara E., additional, Huang, Jeffrey T.-J., additional, and Fardon, Thomas C., additional

Published
2017
Full Text
View/download PDF

28. Clinical phenotypes in adult patients with bronchiectasis

Author

Aliberti, Stefano, primary, Lonni, Sara, additional, Dore, Simone, additional, McDonnell, Melissa J., additional, Goeminne, Pieter C., additional, Dimakou, Katerina, additional, Fardon, Thomas C., additional, Rutherford, Robert, additional, Pesci, Alberto, additional, Restrepo, Marcos I., additional, Sotgiu, Giovanni, additional, and Chalmers, James D., additional

Published
2016
Full Text
View/download PDF

31. Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine mono phosphate challenge in persistent allergic rhinitis.

Author

Lee, Daniel K. C., Jackson, Catherine M., Soutar, Patricia C., Fardon, Thomas C., and Lipworth, Brian J.

Subjects
HISTAMINE, HISTAMINE receptors, RHINITIS, ADENOSINE monophosphate, IMMUNE response, SYMPTOMS, INFLAMMATORY mediators
Abstract

The effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate (AMP) challenge in allergic rhinitis are unknown. We elected to study the effects of usual clinically recommended doses of fexofenadine (FEX), montelukast (ML) and FEX + ML combination, compared with placebo (PL), on nasal AMP challenge in patients with persistent allergic rhinitis. Twelve patients with persistent allergic rhinitis (all skin prick positive to house dust mite) were randomized in a double-blind cross-over fashion to receive for 1 week either FEX 180 mg, ML 10 mg, FEX 180 mg + ML 10 mg combination, or PL, with nasal AMP challenge performed 12 h after dosing. There was a 1-week washout period between each randomized treatment. The primary outcome measure was the maximum percentage peak nasal inspiratory flow (PNIF) fall from baseline over a 60-min period after nasal challenge with a single 400 mg ml−1 dose of AMP. The area under the 60-min time–response curve (AUC) and nasal symptoms were measured as secondary outcomes. There was significant attenuation ( P < 0.05) of the mean maximum percentage PNIF fall from baseline after nasal AMP challenge vs. PL, 48; with FEX, 37; 95% confidence interval for difference 2, 20; ML, 35 (4, 22); and FEX + ML, 32 (7, 24). The AUC (%.min) was also significantly attenuated ( P < 0.05) vs. PL, 1893; with FEX, 1306 (30, 1143); ML, 1246 (214, 1078); and FEX + ML, 1153 (251, 1227). There were no significant differences for FEX vs. ML vs. FEX + ML comparing either the maximum or AUC response. The total nasal symptom score (out of 12) was also significantly improved ( P < 0.05) vs. PL, 3.3; with FEX, 2.1 (0.3, 2.0); ML, 2.0 (0.5, 1.9); and FEX + ML, 2.5 (0.1, 1.4). FEX and ML as monotherapy significantly attenuated the response to nasal AMP challenge and improved nasal symptoms compared with PL, while combination therapy conferred no additional benefit. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results